Research-focused healthcare company Roche has introduced a new point-of care system for the diagnosis and management of metabolic syndrome, which is associated with a higher risk for cardiovascular and type 2 diabetes diseases.
Using blood from a single finger prick, the cobas b 101 system tests glycated hemoglobin (HbA1c) to identify people with high blood glucose levels, and blood lipid panel to determine patients with high risk for heart and blood vessel diseases.
The system, which provides test results in only 15 minutes, also offers early risk assessment and prognosis in patients with metabolic syndrome.
Roche Diagnostics COO Roland Diggelmann said by offering easy to use, fast and precise point-of-care analysis, cobas b 101 system improves patients’ quality of life and clinical outcomes.
"Roche is committed to supporting healthcare professionals with new, more efficient diagnostic tools and helping to reduce healthcare spending by bringing testing to the patient," Diggelmann added.
Roche said the launch of the point-of care system was held globally, excluding the US.